Cargando…
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
INTRODUCTION: Of the more than one million global cases of breast cancer diagnosed each year, approximately fifteen percent are characterized as triple-negative, lacking the estrogen, progesterone, and Her2/neu receptors. Lack of effective therapies, younger age at onset, and early metastatic spread...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446342/ https://www.ncbi.nlm.nih.gov/pubmed/22613095 http://dx.doi.org/10.1186/bcr3192 |